Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
25 Septembre 2024 - 2:30PM
Business Wire
Presentation showcases the profile of EB-003, a
non-hallucinogenic, neuroplastogenic DMT analog, which has shown
positive outcomes in animal models of anxiety and depression
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),
a biotechnology company dedicated to the development of novel
neuroplastogenic small-molecule therapeutics for the treatment of
depression, anxiety, and addiction disorders, today announced that
research highlighting the Company’s lead compound, EB-003, is being
presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a
promising neuroplastogenic and non-hallucinogenic
N,N-Dimethyltryptamine (DMT) analog drug candidate that elicited
beneficial outcomes in preclinical models of anxiety and
depression. The conference is being held at the Hilton Boston Back
Bay in Boston, MA on September 24-26, 2024.
The presentation titled, “Non-hallucinogenic and
neuroplastogenic DMT analog imparts positive behavioral outcomes in
mice,” addresses the criteria researchers evaluated in the design
and development of EB-003 as a non-hallucinogenic derivative of DMT
for the treatment of neuropsychiatric disorders, including
depression and anxiety. The poster highlights key preclinical data
involving EB-003, including two mouse models demonstrating the
effectiveness of EB-003 in reducing anxiety and depression, and
research examining head twitch response (HTR), a behavioral proxy
in rodents for hallucinogenic effects in humans.
This data adds to the library of research supporting the
advancement of EB-003 as Enveric’s lead drug candidate. Recently,
Enveric reported preclinical data confirming the oral
bioavailability of EB-003 and its ability to produce brain exposure
at therapeutically relevant levels. Enveric expects to file an
Investigational New Drug (IND) application for EB-003 by the third
quarter of 2025 and initiate clinical development by the end of
2025.
“The research being presented at the 7th Neuropsychiatric Drug
Summit was foundational in our selection of EB-003 as our lead
product candidate given its potential ability to treat resistant
mental health disorders without the hallucinogenic effect typically
associated with DMT-based molecules and related analogs,” said
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric. “Coupled
with recent evidence demonstrating the ability of EB-003 to achieve
optimal brain exposure after oral dosing, this research affirms our
belief that EB-003 is highly differentiated from similar drugs in
development and has the potential to be a significant value driver
for Enveric and our shareholders.”
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company
dedicated to the development of novel neuroplastogenic
small-molecule therapeutics for the treatment of depression,
anxiety, and addiction disorders. Leveraging its unique discovery
and development platform, Psybrary™, Enveric has created a robust
intellectual property portfolio of new chemical entities for
specific mental health indications. Enveric’s lead program, EB-003,
is a first-in-class approach to the treatment of
difficult-to-address mental health disorders designed to promote
neuroplasticity without inducing hallucinations in the patient.
Enveric is also developing EB-002, a next generation synthetic
prodrug of the active metabolite, psilocin, being studied as a
treatment for psychiatric disorders. Enveric is headquartered in
Naples, FL with offices in Cambridge, MA and Calgary, AB Canada.
For more information, please visit www.enveric.com.
Forward-Looking Statements
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as “plans,” “expects” or
“does not expect,” “proposes,” “budgets,” “schedules,” “estimates,”
“forecasts,” “intends,” “anticipates” or “does not anticipate,” or
“believes,” or variations of such words and phrases, or by the use
of words or phrases which state that certain actions, events or
results may, could, should, would, or might occur or be achieved.
Forward-looking statements may include statements regarding
beliefs, plans, expectations, or intentions regarding the future
and are based on the beliefs of management as well as assumptions
made by and information currently available to management. Actual
results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors,
including, but not limited to, the ability of Enveric to: negotiate
and finalize definitive agreements based on the any of its
out-licensing term sheets and perform pursuant to the terms
thereof; carry out successful clinical programs; achieve the value
creation contemplated by technical developments; avoid delays in
planned clinical trials; establish that potential products are
efficacious or safe in preclinical or clinical trials; establish or
maintain collaborations for the development of therapeutic
candidates; obtain appropriate or necessary governmental approvals
to market potential products; obtain future funding for product
development and working capital on commercially reasonable terms;
scale-up manufacture of product candidates; respond to changes in
the size and nature of competitors; hire and retain key executives
and scientists; secure and enforce legal rights related to
Enveric’s products, including patent protection; identify and
pursue alternative routes to capture value from its research and
development pipeline assets; continue as a going concern; and
manage its future growth effectively.
A discussion of these and other factors, including risks and
uncertainties with respect to Enveric, is set forth in Enveric’s
filings with the Securities and Exchange Commission, including
Enveric’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Enveric disclaims any intention or obligation to revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240925238385/en/
Investor Relations Tiberend Strategic Advisors, Inc.
David Irish (231) 632-0002 dirish@tiberend.com
Media Relations Tiberend Strategic Advisors, Inc. Casey
McDonald (646) 577-8520 cmcdonald@tiberend.com
Enveric Biosciences (NASDAQ:ENVB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Enveric Biosciences (NASDAQ:ENVB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024